Global Biologic & Biosimilar RA Drugs Market Report 2025: Market Opportunities & Challenges Outlook

-

 Aimed at strategic decision-makers, this report explores current opportunities, emerging trends, and market dynamics shaping the biologic & biosimilar ra drugs sector.


How Big Is The Biologic & Biosimilar RA Drugs Market In 2025?
The biologic & biosimilar ra drugs market size has grown steadily in recent years. It will grow from $13.99 billion in 2024 to $14.57 billion in 2025 at a compound annual growth rate (CAGR) of 4.1%. The growth in the historic period can be attributed to market adoption rates, clinical trial outcomes, market share changes, long-term patient outcomes, pricing strategies.

The biologic & biosimilar ra drugs market size is expected to see strong growth in the next few years. It will grow to $19.08 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing biologic drug development, market competition, healthcare policies, patient preferences, clinical research & development. Major trends in the forecast period include rise in biosimilar market competition, personalized medicine and precision therapy, advancements in drug delivery systems, focus on safety and efficacy, patient-centric healthcare.

Get your free sample today:
Biologic & Biosimilar RA Drugs Market Trends & Share Report 2025 Sample

What Are The Major Factors Driving The Biologic & Biosimilar RA Drugs Global Market Growth?
The rising older population and increasing incidence of rheumatoid arthritis are driving the biologics and biosimilar RA drugs market forward. The older population refers to people who are aged 60 years or older. Rheumatoid arthritis is an autoimmune disease in which the immune system of a person attacks its healthy cells, and the joints of the person are affected. Rheumatoid arthritis is most likely to affect people in old age as the immune system gets weaker with old age. Biologics and biosimilar RA drugs are very useful for the treatment of rheumatoid arthritis as compared to conventional drugs. For instance, according to the World Health Organization (WHO), a Switzerland-based specialized health agency of the United Nations, there were about 1 billion people aged 60 and above in the world in 2020 and this population is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050. Furthermore, according to the Centers for Disease Control and Prevention, a US-based governmental public health agency, the number of adults suffering from arthritis in the USA is expected to increase to 78.4 million by 2040 while 34.6 million people may suffer from arthritis-related activity limitations. Therefore, the increasing geriatric population along with the increasing RA cases is driving the biologics and biosimilars RA drugs market forward.

Biologic & Biosimilar RA Drugs Market Report Segmentation Analysis
The biologic & biosimilar ra drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources
2) By Disease: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Other Diseases
3) By Manufacturing: Outsourced, In-House
4) By Mode Of Purchase: Prescription Drugs, Over-The-Counter (OTC) Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines
3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

Emerging Trends And Strategic Opportunities In The Biologic & Biosimilar RA Drugs Market
New innovations are a key trend in gaining popularity in the biologic & biosimilar RA drugs market. Major companies operating in the biologic & biosimilar RA drugs market are focused on developing biosimilar treatments such as Dual Concentration Biosimilar Options to provide an affordable alternative. For instance, in July 2023, Organon, a US-based healthcare company, and Samsung Bioepis, a South Korea-based biopharmaceutical company, launched HADLIMA, a biosimilar of Humira (adalimumab), in the US. Available in high and low concentrations, HADLIMA aims to enhance access and affordability for patients with autoimmune diseases. The biosimilar is priced at an 85% discount to Humira, contributing to expanded patient access. HADLIMA includes an autoinjector, recognized by the Arthritis Foundation, and a patient support program, HADLIMA For You, offering educational resources and co-pay support. It is indicated for various conditions, including rheumatoid arthritis and Crohn's disease. HADLIMA is available in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), providing patients with seamless continuity of care.

What Are The Top Players Operating In The Biologic & Biosimilar RA Drugs Market?
Major companies operating in the biologic & biosimilar RA drugs market include Samsung BioLogics Co. Ltd., Amgen Inc., Novo Nordisk A/S, AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC., Teva Pharmaceutical Industries Ltd., Fresenius Se & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

View the full biologic & biosimilar ra drugs market report here:
Biologic & Biosimilar RA Drugs Market Trends & Share Report 2025

Which Region Holds The Largest Market Share In The Biologic & Biosimilar RA Drugs Market?
North America was the largest region in the biologic & biosimilar RA drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

#Contact Us:#

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


#Follow Us On:#

LinkedIn: The Business Research Company | LinkedIn

Comments

Post a Comment

Popular posts from this blog

Cloud Services Market Evolution 2025-2034: Industry Growth Projections & Market Size Insights

-
 The Business Research Company's report on the Cloud Services Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities. How are market drivers shaping the future growth trajectory of the cloud services industry? The growing adoption of online gaming is expected to propel the growth of the cloud services market going forward. Online gaming refers to video games that are played over the internet or any other computer network available. Cloud services are used in online gaming to provide platform-independent gaming, accessibility, scalability, cost-effectiveness, convenience, and an improved gaming experience. For instance, in March 2023, according to a blog shared by CyberCrew UK, a UK-based online audio and video media company, the number of gamers in the UK had grown by 63% since the 2021 lockdown. Consumers who play video games spent $5.2 billion on them in 2020. I...
Read more

Emerging Template Market Growth Trends: How Fertility Services is Reshaping Market Size & Industry Expansion

-
 The Business Research Company's report on the Fertility Services Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities. How have key drivers contributed to the rapid growth of the fertility services market? Growing infertility rates are anticipated to boost the demand for fertility services during the forecast period. Various social and environment-related factors such as lifestyle changes including obesity, stress or depression, and high consumption of alcohol contribute to a surge in infertility rates, thereby generating a high requirement for fertility services. For instance, in April 2023, according to the World Health Organization (WHO), a Switzerland-based international public health organization, millions of people in the world who are of reproductive age are going to struggle with infertility, which might influence their families and communities. Worldwi...
Read more

Digital Payments Market Evolution 2025-2034: Industry Growth Projections & Market Size Insights

-
 The Business Research Company's report on the Digital Payments Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities. How are market drivers shaping the future growth trajectory of the digital payments industry? Quick onboarding and ease of use are expected to drive the digital payment market. Individuals require flexibility, transparency, and friction-free onboarding. They are more attracted to methods that are frictionless, and as a result, software innovators such as Square and PayPal are using automation to decrease the onboarding time to a few minutes. Digital payments are very easy to use compared to conventional methods, as they only require a bank account or phone number and a smartphone with an internet facility. For instance, according to new data compiled by Taiwan's government, out of a population of about 23 million, nearly 10 million are mobile...
Read more